Overview
Sweden-based medical device maker's Q4 net sales fell significantly yr/yr
Company reported Q4 operating loss amid restructuring and external challenges
Company granted regulatory approval for Clamp System in Australia
Outlook
Redsense aims to increase end-customer usage in the U.S. in 2026
Company plans to launch Redsense Clamp in new markets outside the U.S.
Redsense to implement revised pricing structure from February 2026
Result Drivers
RESTRUCTURING IMPACT - Redsense's restructuring efforts aimed at operational alignment affected Q4 results, with a focus on long-term execution
CURRENCY FLUCTUATIONS - Currency effects impacted Redsense's financial results, with USD/SEK fluctuations affecting reported figures
LOGISTICS CHALLENGES - Elevated logistics and customs costs affected gross margins, prompting a revised pricing structure
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Sales
SEK 6.04 mln
Q4 EPS
-SEK 0.11
Q4 Net Income
-SEK 1.84 mln
Q4 EBIT
-SEK 1.95 mln
Press Release:
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact .